Discovery of Tyrosinase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation

Abstract

Tyrosinase (EC 1.14.18.1) plays an indispensable role in the rate-limiting steps of melanin biosynthesis, and its uncontrolled activity may result in various diseases, such as albinism, melanoma, freckles, etc. The inhibition of tyrosinase activity may provide a useful and efficient strategy to treat hyperpigmentation disorders. However, the widely used tyrosinase inhibitors, like α-arbutin, hydroquinone, and kojic acid, have many shortcomings, such as lower efficacy and much more side effects. Herein, we reported the use of homology modeling and multistep structure-based virtual screening for the discovery of novel tyrosinase inhibitors. In this study, 10 initial potential hits (compounds T1–T10) were evaluated for enzyme inhibition and kinetic study, with kojic acid being used as a control. Among them, the IC₅₀ values of both T1 (11.56 ± 0.98 µmol/L) and T5 (18.36 ± 0.82 µmol/L) were superior to that of kojic acid (23.12 ± 1.26 µmol/L). Moreover, T1 and T5 were also identified as the effective noncompetitive tyrosinase inhibitors by the subsequent kinetic study. Above all, T1 and T5 may represent the promising drug candidates for hyperpigmentation therapy in pharmaceutical fields, as well as the effective whitening agents in cosmetic applications.

Keywords

tyrosinase inhibitors - hyperpigmentation - homology modeling - virtual screening - kinetic study

^# These authors contributed equally to this work.

Publikationsverlauf

Eingereicht: 21. Oktober 2021

Angenommen: 07. Dezember 2021

Artikel online veröffentlicht:
02. März 2022

• References

• 1 Li J, Feng L, Liu L. et al. Recent advances in the design and discovery of synthetic tyrosinase inhibitors. Eur J Med Chem 2021; 224: 113744
• 2 Friedman M. Food browning and its prevention: an overview. J Agric Food Chem 1996; 44: 631-653
• 3 Kramer KJ, Hopkins TL. Tyrosine metabolism for insect cuticle tanning. Arch Insect Biochem Physiol 1987; 6: 279-301
• 4 Pillaiyar T, Namasivayam V, Manickam M, Jung SH. Inhibitors of melanogenesis: an updated review. J Med Chem 2018; 61 (17) 7395-7418
• 5 Boo YC. Human skin lightening efficacy of resveratrol and its analogs: from in vitro studies to cosmetic applications. Antioxidants 2019; 8 (09) 332
• 6 Basak SC, Vracko M, Bhattacharjee AK. Big data and new drug discovery: tackling “Big Data” for virtual screening of large compound databases. Curr Comput Aided Drug Des 2015; 11 (03) 197-201
• 7 Lyu J, Wang S, Balius TE. et al. Ultra-large library docking for discovering new chemotypes. Nature 2019; 566 (7743): 224-229
• 8 Mysinger MM, Shoichet BK. Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 2010; 50 (09) 1561-1573
• 9 Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 2015; 20 (07) 13384-13421
• 10 Waszkowycz B. Towards improving compound selection in structure-based virtual screening. Drug Discov Today 2008; 13 (5–6): 219-226
• 11 Rondeau JM, Schreuder H. Chapter 22 - Protein crystallography and drug discovery. In: Wermuth CG, Aldous D, Raboisson P. et al., eds. The Practice of Medicinal Chemistry. 4th ed.. San Diego: Academic Press; 2015: 511-537
• 12 Mendes E, Perry MdeJ, Francisco AP. Design and discovery of mushroom tyrosinase inhibitors and their therapeutic applications. Expert Opin Drug Discov 2014; 9 (05) 533-554
• 13 Waterhouse A, Bertoni M, Bienert S. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 2018; 46 (W1): W296-W303
• 14 Studer G, Rempfer C, Waterhouse AM, Gumienny R, Haas J, Schwede T. QMEANDisCo-distance constraints applied on model quality estimation. Bioinformatics 2020; 36 (06) 1765-1771
• 15 UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 2021; 49 (D1): D480-D489
• 16 Lai X, Wichers HJ, Soler-Lopez M, Dijkstra BW. Structure of human tyrosinase related protein 1 reveals a binuclear zinc active site important for melanogenesis. Angew Chem Int Ed Engl 2017; 56 (33) 9812-9815
• 17 Ismaya WT, Rozeboom HJ, Weijn A. et al. Crystal structure of Agaricus bisporus mushroom tyrosinase: identity of the tetramer subunits and interaction with tropolone. Biochemistry 2011; 50 (24) 5477-5486
• 18 Zhu D, Huang H, Pinkas DM. et al. 2-Amino-2,3-dihydro-1H-indene-5-carboxamide-based discoidin domain receptor 1 (DDR1) inhibitors: design, synthesis, and in vivo antipancreatic cancer efficacy. J Med Chem 2019; 62 (16) 7431-7444
• 19 Zhang L, Zhang L, Guo Y. et al. MCDB: a comprehensive curated mitotic catastrophe database for retrieval, protein sequence alignment, and target prediction. Acta Pharm Sin B 2021; 11 (10) 3092-3104
• 20 Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1 (04) 337-341
• 21 Fischer A, Smieško M, Sellner M, Lill MA. Decision making in structure-based drug discovery: visual inspection of docking results. J Med Chem 2021; 64 (05) 2489-2500
• 22 Nazir Y, Saeed A, Rafiq M. et al. Hydroxyl substituted benzoic acid/cinnamic acid derivatives: tyrosinase inhibitory kinetics, anti-melanogenic activity and molecular docking studies. Bioorg Med Chem Lett 2020; 30 (01) 126722
• 23 Swinney DC. Chapter 18 - Molecular mechanism of action (MMoA) in drug discovery. In: Macor JE. ed. Annual Reports in Medicinal Chemistry. Cambridge, MA: Academic Press; 2011: 301-317
• 24 Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22 (23) 3099-3108
• 25 Hassan M, Ashraf Z, Abbas Q, Raza H, Seo SY. Exploration of novel human tyrosinase inhibitors by molecular modeling, docking and simulation studies. Interdiscip Sci 2018; 10 (01) 68-80
• 26 Bienert S, Waterhouse A, de Beer TA. et al. The SWISS-MODEL Repository-new features and functionality. Nucleic Acids Res 2017; 45 (D1): D313-D319
• 27 Consortium TU. UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 2021; 49 (D1): D480-D489
• 28 Kataria R, Khatkar A. Molecular docking, synthesis, kinetics study, structure-activity relationship and ADMET analysis of morin analogous as Helicobacter pylori urease inhibitors. BMC Chem 2019; 13 (01) 45-45
• 29 Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput 2012; 8 (08) 2553-2558
• 30 Wang J, Zhu Y, Chen J. et al. Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Acta Pharm Sin B 2020; 10 (04) 603-614
• 31 Luo X, Zhao Y, Tang P. et al. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches. Mol Divers 2021; 25 (01) 367-382
• 32 Adasme MF, Linnemann KL, Bolz SN. et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res 2021; 49 (W1): W530-W534
• 33 Choi J, Choi KE, Park SJ, Kim SY, Jee JG. Ensemble-based virtual screening led to the discovery of new classes of potent tyrosinase inhibitors. J Chem Inf Model 2016; 56 (02) 354-367
• 34 Mutahir S, Khan MA, Khan IU. et al. Organocatalyzed and mechanochemical solvent-free synthesis of novel and functionalized bis-biphenyl substituted thiazolidinones as potent tyrosinase inhibitors: SAR and molecular modeling studies. Eur J Med Chem 2017; 134: 406-414
• 35 Hu YH, Chen QX, Cui Y. et al. 4-Hydroxy cinnamic acid as mushroom preservation: anti-tyrosinase activity kinetics and application. Int J Biol Macromol 2016; 86: 489-495
• 36 Ullah S, Kang D, Lee S. et al. Synthesis of cinnamic amide derivatives and their anti-melanogenic effect in α-MSH-stimulated B16F10 melanoma cells. Eur J Med Chem 2019; 161: 78-92